查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球下呼吸道治療藥物市場 - 2023-2030年
市場調查報告書
商品編碼
1290356

全球下呼吸道治療藥物市場 - 2023-2030年

Global Lower Respiratory Tract Therapeutics Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

全球下呼吸道治療法市場規模在2022年達到323.129億美元，預計到2030年將見證有利可圖的成長，達到562.517億美元。在預測期內（2023-2030年），全球下呼吸道治療法市場預計將呈現7.3%的複合年成長率。關鍵的市場趨勢是行業中與吸煙有關的和吸煙的呼吸道疾病普遍增加。

例如，在2023年4月，密蘇里州的運動推出了"煙草正在改變"，以教育父母不同的糖果味煙草產品誘惑兒童成癮。這也是煙草業的現實- 尤其是在涉及電子煙的時候。

下呼吸道治療學專注於下呼吸道感染疾病和紊亂的診斷、治療和管理這些感染是產科間接死亡的重要原因。懷孕的病人出現呼吸衰竭和肺水腫等併發症的風險增加。下呼吸道治療藥物旨在解決一系列的呼吸道疾病，如哮喘、慢性阻塞性肺病、呼吸道感染、囊性纖維化等。

下呼吸道治療劑市場的驅動因素包括：下呼吸道疾病發病率的增加、老齡人口的增加、認知和診斷的提高、政府計劃和醫療政策、環境因素（如空氣污染、氣候變化和過敏原）以及技術進步。

例如，2023年4月，世界衛生組織（WHO）發布了《普及結核病快速診斷法》，為實現普及WHO推薦的快速診斷法（WRD）設定了基準，以增加細菌學證實的結核病和耐藥性的檢測，並縮短診斷時間。世衛組織推薦的快速診斷法具有高度的準確性和成本效益，縮短了開始治療的時間，並影響到對病人重要的結果。

市場動態

下呼吸道疾病的發病率不斷增加

下呼吸道疾病發病率的增加是在預測期內推動市場佔有率的主要因素。下呼吸道疾病，如哮喘、慢性阻塞性肺病（COPD）、肺炎和支氣管炎，給全球醫療系統帶來了巨大負擔。這些疾病的發病率越來越高，意味著需要有效療法的患者人數越來越多，促使市場需求增加。

例如，2023年5月，血漿衍生藥物和創新診斷解決方案的全球領導者Grifols宣布，它推出了AlphaID家庭遺傳健康風險服務（AlphaID At Home），這是美國有史以來第一個免費直接面對消費者的項目，用於篩查慢性阻塞性肺病的遺傳風險。

不良反應的風險更高

與下呼吸道治療藥物有關的不良反應，如用於治療哮喘或慢性阻塞性肺病的藥物，會引起患者和醫護人員的安全擔憂。不良反應的風險可能使患者不願意開始或繼續治療，促使疾病管理不理想，市場需求減少。

對下呼吸道治療藥物的安全狀況進行持續監測，對於有效識別和管理不良反應至關重要。藥物警戒工作有助於確保早期發現和適當管理不良反應，維持病人的信心和市場需求。

COVID-19影響分析

COVID-19大流行病對醫療保健行業，包括下呼吸道治療藥物市場產生了深遠影響。雖然這場大流行強調了呼吸道健康的重要性，但它也轉移了對其他呼吸道疾病的資源和注意力。此外，供應鏈、臨床試驗和醫療服務的中斷也給市場帶來了挑戰。

這場大流行擾亂了正在進行的下呼吸道治療藥物的臨床試驗。許多試驗被暫停、推遲或修改，以優先考慮COVID-19的研究並確保病人安全。這種臨床試驗活動的中斷可能會推遲新療法的開發和監管部門的批准，影響下呼吸道療法的未來管道。

俄羅斯-烏克蘭衝突分析

俄烏衝突對下呼吸道治療劑市場產生了重大影響。戰爭可能擾亂研發活動，包括新療法或臨床試驗的開發。有限的資源、基礎設施的破壞和研究人員的流離失所會阻礙呼吸道治療劑研究的進展。

衝突可能促使公共衛生方面的挑戰，包括由於過度擁擠、衛生條件差和流離失所而促使呼吸道感染的風險增加。這些因素會促使呼吸道疾病的負擔加重，可能需要增加獲得下呼吸道治療藥物的機會。

目錄

第一章：方法和範圍

  • 研究方法
  • 報告的研究目標和範圍

第二章：定義和概述

第三章：執行摘要

  • 按疾病類型簡述
  • 按藥物類別分類
  • 按給藥途徑分類
  • 按配銷通路分類
  • 按終端用戶分類
  • 按地區分類

第4章：動態變化

  • 影響因素
    • 驅動因素
      • 下呼吸道疾病的發病率不斷上升
      • 有害的環境因素
    • 限制因素
      • 不良反應的風險較高
      • 治療方案有限
    • 機會
      • 治療程序的技術進步
    • 影響分析

第五章：行業分析

  • 波特五力分析
  • 供應鏈分析
  • 價格分析
  • 監管分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情況
    • COVID-19期間的情況
    • COVID-19之後的情況
  • 在COVID-19期間的定價動態
  • 需求-供應譜系
  • 大流行期間與市場有關的政府計劃
  • 製造商的戰略計劃
  • 結語

第七章：按疾病類型

  • 哮喘病
  • 慢性阻塞性肺病
  • 肺炎
  • 結核病
  • 支氣管炎
  • 其他

第8章：按藥物類別分類

  • 抗生素
  • 非類固醇類抗發炎藥
  • 止咳藥
  • 鼻腔減充血劑
  • 其他藥物

第9章：按給藥途徑分類

  • 口服
  • 靜脈注射
  • 其他途徑

第十章：按配銷通路分類

  • 醫院藥房
  • 零售藥店
  • 網上藥店

第十一章：按終端用戶分類

  • 醫院
  • 專科診所
  • 家庭護理
  • 其他

第十二章：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 亞太其他地區
  • 中東和非洲

第13章：競爭格局

  • 競爭格局
  • 市場定位/佔有率分析
  • 合併和收購分析

第十四章：公司簡介

  • F. Hoffmann-La Roche Ltd.
    • 公司概述
    • 產品組合和描述
    • 財務概況
    • 主要發展情況
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi SA
  • Pfizer Inc.
  • GSK plc
  • Novartis AG
  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc

第十五章：附錄

簡介目錄
Product Code: PH558

Market Overview

The Global Lower Respiratory Tract Therapeutics Market size reached US$ 32,312.9 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 56,251.7 million by 2030. The global lower respiratory tract therapeutics market is expected to exhibit a CAGR of 7.3% during the forecast period (2023-2030). The key market trend is the widespread increase in industry smoke-related and smoking respiratory diseases.

For instance, in April 2023, Missouri's campaign launched "Tobacco is Changing", to educate parents about the different candy-flavored tobacco products tempting children into addiction. It is also the reality of the tobacco landscape - especially when it comes to e-cigarettes.

Lower respiratory tract therapeutics focuses on the diagnosis, treatment, and management of diseases and disorders of lower respiratory tract infections These infections are an important cause of indirect obstetric death. Pregnant patients are at increased risk of complications such as respiratory failure and empyema. Lower respiratory tract therapeutics are designed to address a range of respiratory conditions such as asthma, COPD, respiratory infections, cystic fibrosis and so on.

The lower respiratory tract therapeutics market is driven by factors such as the increasing prevalence of lower respiratory tract diseases, the rising aging population, increasing awareness and diagnosis, government initiatives and healthcare policies, environmental factors (such as air pollution, climate change, and allergens), and technological advancements.

For instance, in April 2023, The World Health Organization (WHO) released Universal access to rapid tuberculosis diagnostics, setting benchmarks to achieve universal access to WHO-recommended rapid diagnostics (WRDs) to increase bacteriologically-confirmed TB and detection of drug resistance and reduce the time to diagnosis. WHO-recommended rapid diagnostics are highly accurate, cost-effective, reduce the time to treatment initiation, and impact patient-important outcomes.

Market Dynamics

Increasing Prevalence Of Lower Respiratory Tract Diseases

The increasing prevalence of lower respiratory tract diseases is the major factor driving the market share during the forecast period. Lower respiratory tract diseases, such as asthma, chronic obstructive pulmonary disease (COPD), pneumonia, and bronchitis, impose a significant burden on global healthcare systems. The growing prevalence of these diseases means a larger patient population in need of effective therapeutics, leading to increased market demand.

For instance, in May 2023, Grifols, a global leader in plasma-derived medicines and innovative diagnostic solutions, announced that it launched its AlphaID at-home genetic health risk service (AlphaID At Home), the first-ever free direct-to-consumer program in the U.S., to screen for the genetic risk of COPD.

Higher Risk Of Adverse Effects

Adverse effects associated with lower respiratory tract therapeutics, such as medications used for asthma or COPD, can raise safety concerns among patients and healthcare professionals. The risk of adverse effects may discourage patients from initiating or continuing treatment, leading to suboptimal disease management and reduced market demand.

Continuous monitoring of the safety profile of lower respiratory tract therapeutics is crucial to identify and manage adverse effects effectively. Pharmacovigilance efforts help ensure early detection and appropriate management of adverse effects, maintaining patient confidence and market demand.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a profound impact on the healthcare industry, including the lower respiratory tract therapeutics market. While the pandemic has highlighted the importance of respiratory health, it has also diverted resources and attention away from other respiratory conditions. Additionally, disruptions in supply chains, clinical trials, and healthcare services have posed challenges for the market.

The pandemic has disrupted ongoing clinical trials for lower respiratory tract therapeutics. Many trials were paused, delayed, or modified to prioritize COVID-19 research and ensure patient safety. This interruption in clinical trial activities may delay the development and regulatory approval of new therapies, affecting the future pipeline of lower respiratory tract therapeutics.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict has had a significant impact on the lower respiratory tract therapeutics market. The war may disrupt research and development activities, including the development of new therapies or clinical trials. Limited resources, infrastructure damage, and the displacement of researchers can hinder progress in respiratory therapeutics research.

The conflict can contribute to public health challenges, including the increased risk of respiratory infections due to overcrowding, poor sanitation, and displacement. These factors can lead to a higher burden of respiratory diseases and may require increased access to lower respiratory tract therapeutics.

Segment Analysis

The global lower respiratory tract therapeutics market is segmented based on disease type, drug class, route of administration, distribution channel, end-user, and region.

Based on Disease Type, The Asthma Therapeutics Segment Is Expected To Dominate The Market Share

The market for asthma therapeutics held 45.3% of the global lower respiratory tract therapeutics market share in 2022. Asthma is a prevalent chronic respiratory condition affecting millions of people worldwide. The high prevalence of asthma contributes to a larger patient population requiring ongoing management and treatment, which drives the demand for asthma therapeutics.

Asthma management involves a range of therapeutics to control and prevent symptoms. These include bronchodilators (both short-acting and long-acting), inhaled corticosteroids, combination inhalers, leukotriene modifiers, and monoclonal antibodies targeting specific inflammatory pathways. The availability of multiple treatment options within the asthma therapeutics segment provides choices for healthcare professionals to tailor treatment plans to individual patient needs.

For instance, in May 2023, Alkem Laboratories, a leading pharmaceutical company, announced the launch of its initiative 'Reliever Free India' to raise awareness about Asthma among physicians and Asthma patients. This initiative aims to spread awareness of the hazards of over-usage of reliever medications and substitute it with SMART therapy i.e., needing only one inhaler for both 'daily' and 'reliever' asthma treatment.

Geographical Analysis

North America Holds The Largest Market Share Due To The High Disease Burden And Technological Advancements

North America held 38.1% market share for the lower respiratory tract therapeutics market in 2022 due to the high disease burden and technological advancements in treatment options. North America has a significant burden of lower respiratory tract diseases, including asthma, COPD, and respiratory infections. The region's population, lifestyle factors, environmental exposures, and healthcare infrastructure contribute to the prevalence of these conditions.

North America has witnessed significant technological advancements in the field of respiratory medicine. This includes the development of advanced inhalation devices, targeted biologics, digital health solutions, and precision medicine approaches for lower respiratory tract diseases. These technological advancements enhance treatment efficacy, patient convenience, and disease management, further strengthening the market share of North America.

Competitive Landscape

The major global players in the market include: F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sanofi S.A, Pfizer Inc., GSK plc, Novartis AG, AstraZeneca, Johnson & Johnson Private Limited, Sun Pharmaceutical Industries Ltd., and Merck & Co., Inc.

Why Purchase the Report?

  • To visualize the global lower respiratory tract therapeutics market segmentation based on disease type, drug class, route of administration, distribution channel, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of lower respiratory tract therapeutics market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global lower respiratory tract therapeutics market report would provide approximately 54 tables, 46 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Disease Type
  • 3.2. Snippet by Drug Class
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by End-User
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of lower respiratory tract diseases
      • 4.1.1.2. Harmful environmental factors
    • 4.1.2. Restraints
      • 4.1.2.1. Higher risk of adverse effects
      • 4.1.2.2. Limited treatment options
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological advancements in treatment procedures
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 7.1.2. Market Attractiveness Index, By Disease Type
  • 7.2. Asthma*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. COPD
  • 7.4. Pneumonia
  • 7.5. Tuberculosis
  • 7.6. Bronchitis
  • 7.7. Others

8. By Drug Class

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 8.1.2. Market Attractiveness Index, By Drug Class
  • 8.2. Antibiotics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Non-Steroidal Anti-Inflammatory Drugs
  • 8.4. Cough Suppressants
  • 8.5. Nasal Decongestants
  • 8.6. Others

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Oral*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Parenteral
  • 9.4. Others

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By End-User

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.1.2. Market Attractiveness Index, By End-User
  • 11.2. Hospitals*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Specialty Clinics
  • 11.4. Homecare
  • 11.5. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. The U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. The UK
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Market Positioning/Share Analysis
  • 13.3. Mergers and Acquisitions Analysis

14. Company Profiles

  • 14.1. F. Hoffmann-La Roche Ltd.
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. Teva Pharmaceutical Industries Ltd.
  • 14.3. Sanofi S.A
  • 14.4. Pfizer Inc.
  • 14.5. GSK plc
  • 14.6. Novartis AG
  • 14.7. AstraZeneca
  • 14.8. Johnson & Johnson Private Limited
  • 14.9. Sun Pharmaceutical Industries Ltd.
  • 14.10. Merck & Co., Inc

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us